Announcing a new open access journal

CBD Lipid Signaling is an open access, peer-reviewed, online journal soon to be launched by BioMed Central.

CBD Lipid Signaling will encompass all aspects of research relevant to Lipid Signaling. CBD Lipid Signaling welcomes the submission of all original research articles, commentaries, reports and reviews relating to any aspect of Lipid Signaling research: lipid kinase and phosphatase regulation and signaling, linked pathways, intra- and extracellular actions of bioactive lipids in physiology and disease. Research carried out in any organism will be considered.

CBD Lipid Signaling is associated with the new Targeted Proteins database (TPdb), published by Current BioData, that aims to facilitate use of the growing knowledge of the human proteome to support the needs of scientists involved in drug research. All research articles published in this journal are open access.

All manuscripts submitted to CBD Lipid Signaling will be subject to immediate screening by the Editorial Board. Appropriate manuscripts will be sent to up to 4 referees for review and we will make every effort to reach an initial decision within 4 weeks of submission. If the referees have requested revisions, in general, only one revised version will be considered for further peer-review. All peer review is closed, meaning that referees' confidentiality is maintained and referees reports are not made publicly available. Editorial Board members and referees are asked to declare any competing interests they may have in reviewing a manuscript.

CBD Lipid Signaling is accepting submissions; please use the online submission system to submit your manuscript. For all enquiries about the journal, please contact: editorial@lipidsignaling.cbdjournals.com.

CBD Lipid Signaling is published by BioMed Central, an independent publishing house committed to ensuring peer-reviewed biomedical research is open access - immediately and permanently available online without charge or any other barriers to access.

Learn more about bringing your journal to BioMed Central, the open access publisher.